An FDA-cleared AI tool for breast ultrasound may reduce unnecessary biopsies of benign breast lesions by about 60%.
Key Details
- 1Research presented at RSNA 2025 evaluated the Koios DS AI tool for breast ultrasound.
- 2The study involved 14 breast imaging radiologists and 271 lesions in 253 women, with 76.8% benign and 23.2% malignant lesions.
- 3The AI tool showed 60.6% specificity, assigning many benign lesions to lower BI-RADS categories, and a sensitivity of 90.5%.
- 4The tool misclassified 6 malignant lesions, most of which had other imaging correlates.
- 5Experts emphasized the AI should be used as an adjunct, not a replacement, to radiologist judgment for biopsy decisions.
Why It Matters
Reducing unnecessary biopsies can lower patient anxiety, cut healthcare costs, and ease operational burdens on imaging practices. Integrating AI as a decision-support tool alongside radiologists could lead to more accurate, efficient, and patient-centered breast imaging workflows.
Source
AuntMinnie
Related News
•Radiology Business
CARPL.ai Raises $10M to Expand Radiology AI Marketplace
CARPL.ai secured $10M in Series A funding to expand its global radiology AI marketplace.
•Radiology Business
LLMs Automate Radiology Report Quality Control, Study Finds
LLM-based systems can rapidly automate radiology report quality control, saving significant manual review time.
•AuntMinnie
Radiologists Struggle to Spot AI-Generated Radiology Images
Radiologists correctly identify AI-generated images 75% of the time, with CT and MRI images being particularly challenging to spot.